Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF
机构：[1]Mount Sinai School of Medicine, New York, United States of America[2]Boehringer Ingelheim International GmbH, Ingelheim, Germany[3]Leiden University Medical Center, Leiden, Netherlands[4]University Hospital Essen, Essen, Germany[5]RTI Health Solutions, Research Triangle Park, United States of America[6]Beijing Anzhen Hospital, Beijing, China People’s Republic of首都医科大学附属安贞医院[7]Clinic and Maternity Suizo Argentina, Buenos Aires, Argentina[8]Boehringer Ingelheim GmbH, Ingelheim, Germany[9]Boehringer Ingelheim Corporation, Ridgefield, CT, United States of America[10]Boehringer Ingelheim Corporation, Burlington, Canada[11]University of Birmingham, Birmingham, United Kingdom
第一作者机构：[1]Mount Sinai School of Medicine, New York, United States of America
推荐引用方式(GB/T 7714)：
Halperin J. L.,Teutsch C.,Huisman M. V.,et al.Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF[J].EUROPEAN HEART JOURNAL.2018,39:610-610.
APA：
Halperin, J. L.,Teutsch, C.,Huisman, M. V.,Diener, H. -C.,Rothman, K. J....&Lip, G. Y. H..(2018).Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF.EUROPEAN HEART JOURNAL,39,
MLA：
Halperin, J. L.,et al."Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF".EUROPEAN HEART JOURNAL 39.(2018):610-610
医学